NATCO Pharma LimitedNSE: NATCOPHARM

Press Release Apr 10 2021

· Issued by NATCO Pharma Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

NATCO Pharma Limited has issued a press release announcing the tentative approval of its Ibrutinib tablets by the U.S. Food and Drug Administration. The approval is for multiple strengths of the tablets, which are a generic version of IMBRUVICA. NATCO expects to have a period of sole generic marketing exclusivity upon launch. The press release highlights significant sales figures for IMBRUVICA in the U.S. market.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Natco Pharma Limited has informed the Exchange regarding a press release dated April 10, 2021, titled "NATCO receives tentative approval for Ibrutinib tablets (generic for IMBRUVICA ��) ANDA in the US market".

NATCO Pharma Limited on 6ix

Earlier from NATCO Pharma

Later from NATCO Pharma

All NATCO Pharma news releases